Retatrutide
Proper Handling
Sterile lyophilized powder in a multi-dose vial. Store at controlled room temperature between 20°C and 25°C (68°F - 77°F), protected from light. Reconstitute with bacteriostatic water; do not shake, allow to dissolve naturally or gently swirl. Once mixed, refrigerate the solution at 2°C - 8°C (36°F - 46°F) and use within 30 days. Purity meets or exceeds U.S. Pharmacopeia (USP) regulations and requirements, with every batch undergoing first and third-party testing. Scroll down to view FAQs.
Questions?
Schedule a consultation with a practitioner specialized in peptide therapy, who will determine the best plan for you.
Retatrutide is an investigational treatment for obesity that is a triple hormone receptor agonist. Retatrutide is a gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist.
Retatrutide works in the treatment of obesity by targeting three different hunger regulating hormones:
- GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the gut after eating. It stimulates the beta-cells in the pancreas to secrete insulin.
- GLP-1 (glucagon-like peptide-1) is also an incretin hormone that stimulates the beta-cells to secrete insulin.
- Glucagon is a hormone secreted from the alpha-cells in the pancreas. It stimulates glucose production in the liver and helps maintain adequate plasma glucose concentrations.
The drug has been nicknamed 'triple G' because it is an agonist of all three receptors.
CAS Number 2381089-83-2
PubChem CID 474492335
Molecular Weight 4845.44 g/mol
Molecular Formula C223H343F3N46O70
Synonyms LY-3437943, NOP2Y096GV
GCGR agonists(Glucagon receptor agonists),GIPR agonists(Gastric inhibitory polypeptide receptor agonists),GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Storage (Lyophilized) At 39 Fahrenheit: 2 years
At -4 Fahrenheit: 3 years
This product is sold as a pure compound for research purposes only, unless prescribed by a licensed physician. This product comes in the form of lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Please refer to our terms and conditions prior to purchase.
Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.
The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X
- Urva S, O’Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. doi: 10.1111/dom.15167
- Sinha B, Ghosal S, Mukhopadhyay S, et al. Glucagon-related advancements in diabetes therapy. J Diabetol. 2023;14:S16-S18. doi: 10.4103/jod.jod_96_23
Frequently Asked Questions
Retatrutide
-
Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus, obstructive sleep apnea, osteoarthritis, obesity and non-alcoholic fatty liver disease.
The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.
-
Retatrutide is an injectable peptide administered subcutaneously through the fat. The most fatty parts of the body are the abdomen, side or back of upper arms, and front of thighs.
This peptide is for research purposes only and is still being studied. Schedule a wellness consultation to determine the best plan for your health.
-
The findings from Retatrutide studies unveiled that the predominant treatment‐emergent adverse events linked to Retatrutide are mild or moderate gastrointestinal issues, such as:
- Nausea
- Vomiting
- Diarrhea
- Constipation
Because peptide injections are very similar to peptides that naturally exist in the body and in healthy foods, peptides are typically safe to inject and have very few side effects. The FDA has categorized many peptides as GRAS (considered to be generally recognized as safe) ingredients.
The side effects of peptides depend on the specific type of peptide and the method of consumption. Some common side effects associated with peptides include:
- Injection site reactions such as redness, pain, swelling, bruising and itching
- Flushing sensation
- Digestive issues like nausea, diarrhea, and other digestive symptoms.
- Hormonal imbalances caused by growth hormone-releasing peptides (GHRP)
Remember, everyone reacts differently to substances like Retatrutide due to individual physiological differences such as metabolism rate and overall health status.
-
Retatrutide is a new molecular entity and is not approved by the FDA for human consumption. The only exceptions are for researchers and doctors who can purchase or prescribe Retatrutide under certain conditions.
-
Lyophilized powder is a freeze-dried powder. The shelf life of peptide solutions (commonly cold shipped) is far less than that of lyophilized peptides, and peptides stored in solution are also vulnerable to bacterial degradation.
When storing lyophilized peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability. After opening or reconstituting a peptide with Bacteriostatic Water, peptide solutions are generally stable for up to 45 days when refrigerated at 4C (39F).
If you need instructions to reconstitute your peptide, schedule a wellness consultation.
-
We're happy to help answer questions you may have, or refer you to a licensed healthcare professional for medical advice. Email us at care@somapeptides.com or schedule a wellness consultation.
Your body, your journey.
Millions of people want to know how peptide therapy can help achieve optimal health and performance.
Speak with licensed physicians and specialists in peptide therapy about proper dosage, reconstituting lyophilized peptides, titrating up (or down), and proper care and consideration of your medical history.